Targeting the PI3K/AKT pathway may be a potential therapeutic strategy for patients with Gα13 deletion, since raised pAKT levels may be observed in immunohistochemistry of DLBCL tumors, and high pAKT is linked with poor survival in DLBCL patients [144]. Here, AKT1 is linked to diffuse large B-cell lymphoma.